Background/Aims: The current immunosuppressive treatment of patients with a
utoimmune hepatitis consists of prednisone and azathioprine, High doses of
prednisone used to obtain the remission of the disease are associated with
serious adverse effects, To avoid harmful consequences of prednisone therap
y, we proposed to treat patients with oral cyclosporine to obtain the remis
sion of the inflammatory process.
Methods: This is a pilot, multinational, multicenter, clinical trial involv
ing children with autoimmune hepatitis. Thirty-two children were recruited,
who according to international criteria were considered as having definite
autoimmune hepatitis. Cyclosporine alone was administered for 6 months, fo
llowed by combined low doses of prednisone and azathioprine for 1 month, af
ter which cyclosporine was discontinued. Biochemical remission of the disea
se was established by the follow-up of serum transaminase activity levels.
Growth parameters and adverse effects of the treatment were recorded.
Results: Two patients were withdrawn from the study: one for non-compliance
and the other for liver failure which did not improve with cyclosporine. O
f the 30 remaining patients, 25 normalized alanine aminotransferase activit
y levels by 6 months and all the patients by 1 year of treatment. Z-scores
for height showed a trend towards improvement during treatment. Adverse eff
ects of cyclosporine tr ere mild and disappeared during weaning off the med
ication.
Conclusions: Cyclosporine induced the biochemical remission of the hepatic
inflammatory/necrotic process in children with autoimmune hepatitis, with f
ew and well-tolerated adverse effects.